Dr Falk Pharma and Allianthera sign agreement for ATB102
The companies will work to advance ATB102 to treat inflammatory bowel disease.
Therapy Area
Viridian and Kissei to advance veligrotug and VRDN-003 in Japan
ViroCell and AvenCell to advance allogeneic CAR-T therapy manufacture
MetrioPharm gains orphan drug status from EMA for MP1032
BMS and Bain Capital forge $300m immunology spinoff
Alfasigma sets stage for Jyseleca in axSpA after Phase III win
Re-Vana Therapeutics and Boehringer Ingelheim collaborate for eye therapies
Ascendis Pharma’s Skytrofa gains FDA approval for growth hormone deficiency
